Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NASDAQ:NK NYSE:PLX NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.52-3.8%$1.85$1.12▼$4.20$113M0.92200,395 shs83,516 shsNKNantKwest$2.37-3.7%$28.01$2.52▼$45.42$259.15M2.611.57 million shs7.05 million shsPLXProtalix BioTherapeutics$1.45-0.7%$1.50$0.82▼$3.10$115.43M-0.23864,151 shs357,101 shsPRMEPrime Medicine$4.04+8.0%$2.82$1.11▼$5.18$543.36M2.332.39 million shs4.71 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics-3.80%-14.12%-17.84%-32.44%+7.80%NKNantKwest-3.91%-18.27%-4.28%-3.15%-52.23%PLXProtalix BioTherapeutics-0.68%-3.97%-3.33%-51.67%+34.26%PRMEPrime Medicine+8.02%-4.04%+31.60%+140.48%-27.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics2.0623 of 5 stars3.33.00.00.01.50.01.3NKNantKwestN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.2169 of 5 stars3.53.00.00.00.00.01.9PRMEPrime Medicine3.7426 of 5 stars4.41.00.00.03.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50327.63% UpsideNKNantKwest 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00934.48% UpsidePRMEPrime Medicine 2.75Moderate Buy$9.25128.96% UpsideCurrent Analyst Ratings BreakdownLatest NK, PRME, IKT, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ANKNantKwest$40K6,478.69N/AN/A$1.23 per share1.93PLXProtalix BioTherapeutics$59.76M1.93$0.08 per share17.80$0.47 per share3.09PRMEPrime Medicine$3.85M141.28N/AN/A$1.37 per share2.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ANKNantKwest-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ALatest NK, PRME, IKT, and PLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ANKNantKwestN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4535.79%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85NKNantKwestN/A4.744.74PLXProtalix BioTherapeuticsN/A1.981.27PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%NKNantKwest9.38%PLXProtalix BioTherapeutics16.53%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%NKNantKwest71.73%PLXProtalix BioTherapeutics6.50%PRMEPrime Medicine22.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableNKNantKwest160109.35 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePRMEPrime Medicine234134.50 million100.38 millionOptionableNK, PRME, IKT, and PLX HeadlinesRecent News About These CompaniesPrime Medicine Halts Sales Agreement ProspectusAugust 1 at 8:50 PM | theglobeandmail.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesAugust 1 at 8:50 PM | finance.yahoo.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesAugust 1 at 4:01 PM | globenewswire.comPrime Medicine (NYSE:PRME) Shares Gap Down - Here's WhyAugust 1 at 1:11 PM | marketbeat.comPrime Medicine stock falls after pricing public offeringAugust 1 at 4:11 AM | za.investing.comJonesTrading Maintains a Buy on Prime Medicine (PRME)August 1 at 4:11 AM | msn.comPrime Medicine (NYSE:PRME) Trading Up 6.9% - Here's WhyJuly 31 at 2:54 PM | marketbeat.comPrime Medicine Announces Pricing of Public OfferingJuly 30 at 9:33 PM | globenewswire.comPrime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial StatementsJuly 30 at 9:11 PM | globenewswire.comPrime Medicine (NYSE:PRME) Trading Down 8.9% - Here's WhyJuly 30 at 4:32 PM | marketbeat.comPrime Medicine Announces Proposed Public Offering of Common StockJuly 30 at 4:01 PM | globenewswire.comPrime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?July 30 at 10:55 AM | zacks.com3 Genomics Stocks Worth Adding to Your Portfolio in 2025July 30 at 10:45 AM | zacks.comARK Investment Management LLC Sells 2,055,061 Shares of Prime Medicine, Inc. (NYSE:PRME)July 27, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Shares Sold by Nikko Asset Management Americas Inc.July 27, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Receives $9.25 Consensus Price Target from BrokeragesJuly 27, 2025 | americanbankingnews.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 24, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 23.3% - Here's WhyJuly 21, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 6.6% - Time to Sell?July 18, 2025 | marketbeat.comWedbush Has Positive Forecast for Prime Medicine Q2 EarningsJuly 18, 2025 | marketbeat.comPrime Medicine's (PRME) "Outperform" Rating Reiterated at WedbushJuly 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth TrendsIs Amazon Really the Best Forever Stock for Your Portfolio?By Sam Quirke | July 17, 2025View Is Amazon Really the Best Forever Stock for Your Portfolio?Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead4 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025View 4 Stocks Planning to Substantially Boost Buybacks After Solid Q2Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsBy Sam Quirke | July 21, 2025View Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsNK, PRME, IKT, and PLX Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.52 -0.06 (-3.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.52 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.NantKwest NASDAQ:NKNantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Protalix BioTherapeutics NYSE:PLX$1.45 -0.01 (-0.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.03%) As of 08/1/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Prime Medicine NYSE:PRME$4.04 +0.30 (+8.02%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.34 +0.30 (+7.33%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
